Institut national d'excellence en santé et en services sociaux Québec • •

COMMUNITY PHARMACIST LIAISON FORM

Initiating pharmacological treatment for oropharyngeal mucositis in a patient receiving cancer therapy

No. 888029

Collective prescription number (if applicable Institution:):	PATIENT IDENTIFICATION Last name: First name: Date of birth: Health insurance number:
PHARMACY (OR PHARMACIST)	IDENTIFICATION	
NAME:		
TELEPHONE NUMBER:	FAX NUMBER:	
form will not be reused.		rs above is the only recipient. The original of this
DRUG IDENTIFICATION AND DOSAG	iE .	
☐ First-line oncology mouthwash		
Diphenhydramine Hydrocortisone Magnesium/aluminium hydroxide Nystatin Sterile water Dosage: 15 to 30 ml QID until symptom res Stability: 14 days in refrigerator	250 ml elixir (12.5 mg/5 ml) or of 100 mg powder or tablets (10 x 165 ml oral suspension (200-2062 ml oral suspension (100,000 q.s. to 500 ml solution	10 mg or 5 x 20 mg) 0 mg/5 ml)
\square Oncology mouthwash with lidocaine		
Diphenhydramine Viscous lidocaine Magnesium/aluminium hydroxide Sterile water	200 ml elixir (12.5 mg/5 ml) or 200 ml 2% oral topical gel 200 ml oral suspension (200-2 q.s. to 600 ml, if necessary	·
Dosage: 15 to 30 ml QID until symptom res Stability: 14 days in refrigerator	solution	
*For additional information, consult Québec	national medical protocol No. 888	3029 on INESSS's website.
IDENTIFICATION OF THE HEALTH PR	ROFESSIONAL WHO EXECU	TES THE PRESCRIPTION
Name, Surname:		
Practice license number:		
Telephone number:		
Signature:	Date:	
PRESCRIBING PHYSICIAN IDENTIFIC	CATION	
Name, Surname:		
Practice license number:		
Telephone number:		

FAX TRANSMITTAL TO COMMUNITY PHARMACY (to be completed only if the sender is different from the authorized professional)

Sender's Name:

Date and time fax sent: